ESTRO 2024 - Abstract Book

S4561

Physics - Machine learning models and clinical applications

ESTRO 2024

[inter quartile range(IQR)=0.05] to 0.21 [IQR=0.07] and 0.19 [IQR=0.07] for, respectively, the MUlimit and ASC reoptimization (Figure 2). The predicted_GPR was significant improved, from 93.3% [IQR=5.1%] to 94.4% [IQR=5.3%] (MUlimit) and to 95.0%[IQR=4.9%] (ASC) (Figure 2). The measured_GPR were improved, in particular the median value increase from 99.3% [IQR=1.6%] (original plan) to 99.7% [IQR=0.8%] (MUlimit) and 99.5% [IQR=0.7%] (ASC) (Figure 2). Plan constraints were respected with no significant difference between the three groups. However, a median increase of 3% [IQR=0.05] (on MUlimit) and 2% [IQR=0.04] (on ASC) in dose to OARs, of 3% [IQR=0.49] (MUlimit) and 1% [IQR=0.17] (ASC) to the body, and a reduction of 2% [IQR=0.6] in dose to the PTV and the CTV was obtained (Figure 2).

Conclusion: